Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2008
Business Overview: Cardinal Health is a leading provider of healthcare products and services, operating primarily through two sectors: Healthcare Supply Chain Services (distribution of pharmaceuticals and medical products) and Clinical and Medical Products (manufacturing of medical technologies and surgical products). As of the reporting date, the company operated four reportable segments, though it announced a reorganization effective July 1, 2008, to consolidate into three segments. The company serves retail pharmacies, hospitals, and alternate care providers.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Revenue | $91,091.4 million | $86,852.0 million |
| Gross Margin | $5,634.1 million | $5,245.3 million |
| Operating Earnings | $2,121.2 million | $1,373.7 million |
| Net Earnings | $1,300.6 million | $1,931.1 million |
| Diluted EPS | $3.57 | $4.77 |
| Cash from Operating Activities | $1,559.1 million | $1,003.0 million |
| Total Assets | $23,448.2 million | $23,153.8 million |
| Long-term Obligations | $3,687.4 million | $3,457.3 million |
| Shareholders' Equity | $7,747.5 million | $7,376.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5% to $91.1 billion, driven by pharmaceutical price appreciation (7.7% index), volume growth from bulk customers, and acquisitions (notably Viasys and Enturia). This was partially offset by a loss of customers ($2.1 billion), largely due to DEA license suspensions.
- Profitability: Operating earnings rose 54% to $2.1 billion. This increase was primarily due to the absence of a $600 million litigation settlement expense recorded in fiscal 2007. Gross margin increased by $389 million, while SG&A expenses rose by $333 million.
- Net Earnings Decline: Despite higher operating earnings, Net Earnings decreased 33% to $1.3 billion. This decline was driven by a $1.1 billion after-tax gain on the sale of the Pharmaceutical Technologies and Services (PTS) Business recorded in fiscal 2007, which was not present in fiscal 2008.
- Segment Performance: The Healthcare Supply Chain Services-Pharmaceutical segment profit declined 14% due to increased customer discounts and DEA-related disruptions. Conversely, the Medical Products and Technologies segment profit surged 52% due to the Viasys acquisition.
Guidance, Outlook, and Risks
- Strategic Separation: On August 7, 2008, the Board supported exploring a potential separation of the Healthcare Supply Chain Services and Clinical and Medical Products segments, potentially via a tax-free spin-off. A decision is expected within 60 to 90 days.
- Regulatory Risks: The company faces significant regulatory scrutiny. The DEA suspended licenses for three distribution centers in late 2007; an oral agreement in principle to resolve this was reached in August 2008, with a $34 million reserve recorded. The company is also subject to ongoing IRS audits regarding tax years 2001-2005, with proposed adjustments totaling over $770 million (excluding penalties).
- Cost Pressures: Management expects fiscal 2009 results to be negatively impacted by rising oil and commodity costs. The company plans to offset these through cost reductions and potential price increases.
- Dividends: The quarterly dividend was raised by 17% to $0.14 per share in the fourth quarter of fiscal 2008.
Investor Verification Checklist
- DEA Resolution: Verify the final terms and timeline for the lifting of DEA license suspensions and the impact on future revenue from non-bulk customers.
- Tax Contingencies: Review the status of IRS audits for fiscal years 2001-2005 and the potential impact of the $770+ million in proposed adjustments on future tax provisions.
- Segment Separation: Monitor the outcome of the potential spin-off of the Clinical and Medical Products segment and its impact on capital allocation and share repurchases.
- Customer Concentration: Note that the top five customers (including CVS and Walgreens) accounted for 52% of revenue; assess the risk of contract repricing or volume shifts.
- Acquisition Integration: Evaluate the integration progress and cost synergies from the Viasys and Enturia acquisitions, which drove significant growth in the Medical Products segment.